Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in ...

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

A novel immunotherapy could lead to a brain cancer breakthrough after showing promising results against glioblastoma, the ...

Misako Nagasaka, MD, PhD, discusses optimizing patient management when administering frontline SC amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. She ...

Misako Nagasaka, MD, PhD, discusses the overall response rate and duration of response with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced ...

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while ...

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

Brain cancer breakthrough as new study finds cell therapy could target deadly glioblastoma - Patients diagnosed with ...

Researchers at UCLA found that creatine not only enhances cancer-fighting killer T cells but also strengthens dendritic cells, which activate and direct T cells to attack tumors.

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly ...

Scientists have cracked how bacteria build cancer-fighting compounds, a breakthrough that could speed up new treatments. The ...

The review draws the formal regulatory distinction: gene therapy involves the deliberate and permanent alteration of a patient's genome. mRNA vaccines do not ...